Topic: How To Invest

Wall Street Stock Forecaster Hotline – Friday, December 9, 2016

Article Excerpt

PFIZER INC., $31.70, New York symbol PFE, New York symbol PFE, is one of the world’s leading prescription drugmakers. Its top-selling brands include Lyrica (epilepsy), Celebrex (arthritis pain) and Enbrel (plaque psoriasis, rheumatoid arthritis). The company also makes over-the-counter medications and supplements, including Advil (pain relief), Centrum (vitamins) and Robitussin (cough syrup). In 2012, Pfizer entered an agreement with Flynn Pharma to sell its U.K. distribution rights for the epilepsy treatment Epanutin. This week, British regulators fined Pfizer and Flynn for charging “excessive and unfair prices” for the drug. They accused the companies of removing the Epanutin brand from these pills, which let them increase their selling price by up to 2,600%. Pfizer’s share of the fine is 84.2 million British pounds, or roughly $106 million U.S. That’s small next to the $3.7 billion, or $0.61 a share, it earned in the three months ended September 30, 2016. Even so, the company plans to appeal this ruling. OUR RECOMMENDATION: Pfizer is our top Income buy…